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The Editorial on the Research Topic
How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?
Among many sources of hematopoietic stem cells (HSCs), cord blood (CB) belongs to the earliest 
stages of life, rich of stem cells with longest telomeres and capable of the longest life-span follow-
ing transplantation (1). Thus, CB has many features resembling fetal or even embryonic stem cells. 
Although stem cell content of CB was known for a long time the first and also successful human 
cord blood transplantation (CBT) was made possible in 1988. So far, more than 30,000 CBTs have 
been performed worldwide. Although the initial experience began with CBTs from human leukocyte 
antigen (HLA)-matched sibling CB, later unrelated CB has become the major source (Beksac). Ease 
of procurement and lack of donor attrition, with the ability to process and store the donor cells long 
term make CB as an attractive HSC source. Importantly, high proliferative potential of the immature 
HSCs allows one log less use of cells compared to bone marrow (BM) or peripheral blood stem cells. 
Furthermore, due to the immune nature of CB, it provides an excellent alternative source of HSC 
for patients lacking HLA-matched donor. Up to two out of six HLA antigen mismatches are easily 
acceptable.
Cord blood is either donated to public CB banks for use by any patient worldwide for whom it is a 
match or stored in a private bank for potential autologous or family use. In this mini-review, there is 
a chapter by Armitage on the regulations, standards, and accreditations schemes currently available 
nationally and internationally for public and private CB banking. Currently, most of private banking 
is not regulated as strictly as public CB banks. Regulations and standards were initially developed to 
address the public banking. However, the importance of quality concept and accreditation is gradu-
ally becoming recognized by autologous and hybrid banks. Greater success rate of cords coming 
from accredited CBBs is also a scientifically recognized finding (2). To ensure success and the true 
realization of the full potential of CB, whether for autologous or allogeneic use, it is essential that 
each and every product meets high-quality, international standards. Authorities, such as AABB and 
FACT/NETCORD, aim to ensure quality among CBBs worldwide.
In spite of all the above listed advantages, there are limitations, such as low cell dose, which is asso-
ciated with prolonged time to engraftment, risk of graft rejection, infections, and treatment-related 
mortality. To increase the cell dose, a variety of ex vivo expansion techniques have been developed. In 
this mini-review, there is a chapter written by the group led by Shpall, MD Anderson Cancer Center. 
They will discuss their pioneering experience of expanding CB cells with mesenchymal progenitor 
cells (Mehta et al.) and other methods such as use of HPC-differentiation blockers, i.e., nicotinamide 
analogs, copper chelators, inducing constitutive Notch signaling, or an aryl hydrocarbon receptor 
antagonist (StemReginin1). Many of these methods lead to substantial expansions of CD34+ cells, 
and significantly improving time to engraftment in patients transplanted with the expanded products 
compared to the recipients of unmanipulated CBT.
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Following allogeneic CBT, the risk of relapse and graft- 
versus-host disease (GVHD) are lower than what is typically 
observed after other graft sources with a similar degree of HLA 
mismatch. Natural killer (NK) cells have a well-defined role in 
both innate and adaptive immunity and as the first lymphocytes 
to reconstitute after HSCT and CBT, and they play a significant 
role in protection against early relapse. In this mini-review, The 
MD Anderson Cancer Center Group led by Rezvani will focus on 
the uses of CB NK cells in transplantation and adoptive immu-
notherapy (Mehta et al.). First, they will describe differences in 
the phenotype and functional characteristics of NK cells in CB 
compared to BM or peripheral blood. Then, they will review the 
obstacles arising from use of resting CB NK cells, and methods 
to overcome them. In addition, the current literature on killer-
cell immunoglobulin-like receptor (KIR)–ligand mismatch and 
outcomes after CBT will be presented.
In addition to their strategies to increase the HSC content, 
methods to increase homing have also been developed. In 
this mini-review, a chapter will describe modalities such as 
intra-bone administration, fucosylation, CD26 inhibition, 
prostaglandin E2 derivative or complement 3 exposure, and 
SDF-1/CXCR4/CXCL-12 pathway modulations that have 
been experimented successfully (Beksac and Yurdakul). These 
in vivo and in vitro applications have yielded satisfactory results, 
which led to early phase clinical trials revealing faster in vivo 
engraftment.
Transplant Registry data from CIBMTR or WBMT show 
that approximately 9–15% of allogeneic transplants are being 
transplanted from CB (3, 4). Choice of CB as a stem cell source is 
determined by multiple factors including availability of successful 
institutional protocols or experience and country/population/
donor-CB registry characteristics. Recently, there is a gradual 
decrease in the number of CBTs. Although CBs are easily acces-
sible, high CB fees or alternative stem cell sources are limiting 
factors against wider use of single and double CBTs. The biggest 
challenge against CBT is the documented delay in myeloid and 
lymphoid engraftment. Nevertheless, presence of hereditary dis-
eases within the family or lack of haploidentical family members 
suitable for stem cell donation makes CB an option when no 
matched unrelated donor is available.
In summary, recent developments described here are very 
promising toward overcoming hurdles and the rebirth of CBT.
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